K. Gregor

发表

The use of two measures of health-related quality of life in HIV-infected individuals: a cross-sectional comparison

A. Wu, N. Ampel, S. Coons, 1996, Quality of Life Research.

Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol

K. Gregor, E. Edgell, S. Hamilton, 2000, Schizophrenia Research.

An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France

C. Pen, M. Allicar, M. Bouhassira, 1999, Schizophrenia Research.

Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.

E. Vieta, A. Montejo, J. Sacristán, 2000, Clinical therapeutics.

Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.

K. Gregor, E. Edgell, I. Cockburn, 1999, Clinical therapeutics.

The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment

J. Alonso, J. Haro, M. Knapp, 2003, Acta psychiatrica Scandinavica.

PCN3: COST ANALYSIS OF SCHIZOPHRENIA TREATMENT IN GERMANY: A COMPARISON OF OLANZAPINE, RISPERIDONE, AND HALOPERIDOL USING A CLINICAL DECISION MODEL

K. Gregor, J. Clouth, A. Spannheimer, 1999 .

Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?

S. James, K. Gregor, C. H. Young, 1997, Journal of affective disorders.

Antipsychotic treatment and changes in health related quality of life in patients with schizophrenia using EQ-5D

X. Badia, J. Sacristán, K. Gregor, 2000, Schizophrenia Research.